AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LTR PHARMA LTD

0.540

+0.05010.20%

Volume:295.84K

Turnover:158.26K

Market Cap:98.09M

PE:-16.15

High:0.555

Open:0.490

Low:0.490

Close:0.490

52wk High:0.810

52wk Low:0.270

Shares:181.65M

Float Shares:100.83M

Volume Ratio:1.92

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.033

EPS(LYR):-0.033

ROE:-32.47%

ROA:-21.45%

PB:3.11

PE(LYR):-16.15

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

LTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%

MT Newswires Live

LTR Pharma Doses First Patient in Phase Two Study of Spontan; Shares Up 4%

MT Newswires Live

LTR Pharma Launches Phase II Trial of Erectile Dysfunction Treatment Candidate

MT Newswires Live

LTR Pharma Says Over 1,000 Spontan Prescriptions Issued Under TGA Special Access Scheme

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LTP.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LTP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","market":"AU","secType":"STK","nameCN":"LTR PHARMA LTD","latestPrice":0.54,"timestamp":1770694500128,"preClose":0.49,"halted":0,"volume":295841,"delay":0,"changeRate":0.10204081632653071,"nameEN":"LTR PHARMA LTD","floatShares":100829062,"shares":181645077,"eps":-0.033444,"marketStatus":"Trading","change":0.05,"latestTime":"02-10 14:41:08 AEDT","open":0.49,"high":0.555,"low":0.49,"amount":158260,"amplitude":0.132653,"askPrice":0.545,"askSize":26554,"bidPrice":0.53,"bidSize":5939,"shortable":3,"etf":0,"ttmEps":-0.033444,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"listingDate":1702126800000,"exchange":"ASX","adjPreClose":0.49,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.922357,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","floatShares":100829062,"roa":"-21.45%","roe":"-32.47%","lyrEps":-0.033444,"volumeRatio":1.922357,"shares":181645077,"dividePrice":0,"high":0.555,"amplitude":0.132653,"preClose":0.49,"low":0.49,"week52Low":0.27,"pbRate":"3.11","psRate":"65.03","week52High":0.81,"institutionHeld":0,"latestPrice":0.54,"committee":-0.634444,"eps":-0.033444,"divideRate":0,"volume":295841,"delay":0,"ttmEps":-0.033444,"open":0.49,"prevYearClose":0.72,"prevWeekClose":0.49,"prevMonthClose":0.545,"prevQuarterClose":0.72,"fiveDayClose":0.53,"twentyDayClose":0.64,"sixtyDayClose":0.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LTP.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608739831","title":"LTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608739831","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608739831?lang=en_us&edition=fundamental","pubTime":"2026-02-02 12:22","pubTimestamp":1770006150,"startTime":"0","endTime":"0","summary":"LTR Pharma  said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.LTR Pharma's shares fell 6% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2605374455","title":"LTR Pharma Doses First Patient in Phase Two Study of Spontan; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605374455","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605374455?lang=en_us&edition=fundamental","pubTime":"2026-01-22 10:55","pubTimestamp":1769050521,"startTime":"0","endTime":"0","summary":"LTR Pharma  has dosed the first patients in the phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray to treat erectile dysfunction, signaling the shift from recruitment to active data collection, according to a Thursday Australian bourse filing.The study is evaluating single and multiple dose pharmacokinetics in around 27 healthy male participants across three cohorts, with about half aged 65 or older in line with US Food and Drug Administration geriatric guidance, per the filing.The study remains on track, with initial data expected in the second quarter, the filing added.The company's shares rose 4% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2603212855","title":"LTR Pharma Launches Phase II Trial of Erectile Dysfunction Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2603212855","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603212855?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:29","pubTimestamp":1768256995,"startTime":"0","endTime":"0","summary":"LTR Pharma  started patient recruitment for the phase II pharmacokinetic trial of Spontan, an intranasal spray being developed to potentially treat erectile dysfunction, according to a Tuesday Australian bourse filing.The study will assess single and multiple dose pharmacokinetics in about 27 healthy male participants across three groups, with around half aged 65 or older to meet US Food and Drug Administration geriatric-use guidance, the filing said.The trial is designed to generate important prescribing insights for older men, a group that is frequently prescribed lower doses of oral phosphodiesterase type 5 inhibitors, such as Viagra and Cialis, per the filing.Recruitment follows full regulatory approvals for the study, including clearance from the Human Research Ethics Committee at Bellberry and acceptance of the company's clinical trial notification by the Therapeutic Goods Administration, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2592957089","title":"LTR Pharma Says Over 1,000 Spontan Prescriptions Issued Under TGA Special Access Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2592957089","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592957089?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:58","pubTimestamp":1765940328,"startTime":"0","endTime":"0","summary":"LTR Pharma  said over 1,000 prescriptions of Spontan had been issued in Australia under the Therapeutic Goods Administration  Special Access Scheme, according to a Wednesday Australian bourse filing.Under the scheme, clinicians can request access to Spontan where approved treatments are unsuitable, ineffective, or unavailable.De-identified data collection from the prescriptions under the scheme is ongoing.Its shares rose 2% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7001","BK7096","BK4213","TGA","TGA.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LTP.AU\",params:#limit:6,delay:true,,,undefined,":[]}}